Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors. To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending. Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over €70 million in funding since inception. *


Period Start 1999-01-01 established
  Group Cellectis (Group)
Products Industry genome editing (gene editing)
  Industry 2 TALEN® technology (Transcription Activator-Like Effector Nuclease)
Persons Person Choulika, André (Cellectis 200701 CEO + co-founder)
  Person 2 Dutang, Eric (Cellectis 2016– CFO joined 201505)
Region Region Romainville
  Country France
  Street 8 Rue de la Croix Jarry
  City 75013 Paris
  Tel +33-1-8169-1600
    Address record changed: 2020-12-02
Basic data Employees D: 101 to 500 (2019-12-31)
  Currency USD
  Annual sales 22,990,000 (income, total, consolidated (2019) 2019-12-31)
  Profit -115,212,000 (2019-12-31)
  Cash 340,522,000 (2019-12-31)
    * Document for �About Section�: 
Record changed: 2021-02-17


Picture [iito] Plain Stupid Simple 650x80px

More documents for Cellectis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px

» top